Sex-related differences in treatment outcomes of chronic hepatitis C with direct-acting antivirals

doi:10.4254/wjh.v17.i10.110430

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 10

This Article

(41)

(71)

(0)

(8)

(2010)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Oct 27, 2025; 17(10): 110430
Published online Oct 27, 2025. doi: 10.4254/wjh.v17.i10.110430

Table 3 Summary of sustained virologic response and adverse events stratified by age and sex, n (%)

Parameter	Category	15-44 years		45-55 years		> 55 years
Parameter	Category	Women (n = 3118)	Men (n = 4163)	Women (n = 1689)	Men (n = 2185)	Women (n = 4650)	Men (n = 3181)
SVR12	Intent-to-treat (%)	96.44	93.42	96.09	91.17	95.83	92.96
SVR12	Per protocol (%)	98.95	93.37	98.66	94.99	98.00	96.86
AEs	At least one AE	457 (14.66)	491 (11.79)	319 (18.9)	332 (15.19)	918 (19.74)	544 (17.1)
Common AEs	Weakness/fatigue	187 (6)	178 (4.28)	140 (8.29)	143 (6.54)	349 (7.51)	232 (7.29)
Common AEs	Headache	113 (3.63)	69 (1.66)	55 (3.26)	33 (1.51)	118 (2.54)	47 (1.48)
Severe AEs	LT, HCC, DLC	7 (0.22)	17 (0.41)	11 (0.65)	19 (0.87)	71 (1.53)	57 (1.79)
Adverse effects of special interest	Ascites	8 (0.26)	12 (0.29)	7 (0.41)	19 (0.87)	35 (0.75)	48 (1.51)
	HE	2 (0.06)	9 (0.22)	6 (0.36)	12 (0.55)	17 (0.37)	34 (1.07)
	GI bleeding	1 (0.03)	8 (0.19)	2 (0.12)	5 (0.23)	8 (0.17)	7 (0.22)
Death	Death	1 (0.03)	10 (0.24)	6 (0.36)	11 (0.5)	31 (0.67)	54 (1.7)

AEs: Adverse events; DLC: Decompensation of liver cirrhosis; GI: Gastrointestinal; HE: Hepatic encephalopathy; HCC: Hepatocellular carcinoma; LT: Liver transplantation; SVR12: Sustained virologic response at 12 weeks post-treatment.

Full Size Table

Citation: Feyissa GD. Sex-related differences in treatment outcomes of chronic hepatitis C with direct-acting antivirals. World J Hepatol 2025; 17(10): 110430
URL: https://www.wjgnet.com/1948-5182/full/v17/i10/110430.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i10.110430

Feyissa GD. Sex-related differences in treatment outcomes of chronic hepatitis C with direct-acting antivirals. World J Hepatol 2025; 17(10): 110430 [PMID: 41179721 DOI: 10.4254/wjh.v17.i10.110430]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.